Evotec's EVT 201 meets insomnia endpoint

Evotec (FSE:EVT) said both doses of EVT 201 (1.5 and 2.5 mg) met the primary endpoint of a significant improvement in total sleep time in a Phase II trial to treat insomnia. Compared with placebo, mea...